The Tres Cantos Open Lab Foundation was established as a not-for-profit organisation and operates independently of GSK through its Governing Board and Trustees.
The Governing Board is comprised of world-leading experts in the field of research into diseases of the developing world who advise and guide the Foundation in meeting its objectives. The Board also ensures that projects selected are of a consistently high standard and address the three diseases areas. The Board includes the Trustees of the Foundation and is chaired by Professor Sir Leszek Borysiewicz, Vice-Chancellor of the University of Cambridge.
Professor Fairlamb is Head of the Division of Biological Chemistry and Drug Discovery at the University of Dundee. He obtained his degree in Medicine and PhD in Biochemistry at the University of Edinb...more
Carl Nathan, MD is R.A. Rees Pritchett Professor and chairman of the Department of Microbiology and Immunology at Weill Cornell Medical College and co-chair of the Program in Immunology and Microbial ...more
Jose-Maria Romero is responsible for the negotiation of worldwide deals with other pharmaceutical and biotech companies to access new products which complement and increase the value of GSK’s ph...more
Dave Allen is the head of the Respiratory Therapy Area at GSK and is responsible for the identification of novel differentiated medicines and their progression to registration and launch. He leads a g...more
Dr Bilbe has the overall responsibility for advancing the discovery and development of new treatments for neglected diseases and building DNDi’s project portfolio.Prior to joining DNDi in 2012, ...more
Dr R. Kip Guy is currently the Dean of Pharmacy and a Professor of Pharmaceutical Sciences at the University of Kentucky in Lexington, Kentucky, USA.Dr Guy obtained his BA in chemistry from Reed Colle...more
Dr. Mel Spigelman is the President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance). Prior to being appointed President and CEO in 2009, Dr. Spigelman served fo...more
Dr Timothy Wells joined Medicines for Malaria Venture in October 2007 as the Chief Scientific Officer. He has responsibility for the Research and Development Portfolio, which covers over 50 projects f...more
Elizabeth Ann Winzeler is a Professor in the Department of Pediatrics at University of California, San Diego, School of Medicine with experience in academic and industrial antimicrobial drug discovery...more